Drug Profile
Research programme: metabolic disorder therapies - Pfizer
Latest Information Update: 13 Mar 2008
Price :
$50
*
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 06 Apr 2006 Preclinical trials in Obesity in USA (unspecified route)
- 06 Apr 2006 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)